ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

SAGE Sage Therapeutics Inc

13.71
0.605 (4.62%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Sage Therapeutics Inc SAGE NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.605 4.62% 13.71 14:00:08
Open Price Low Price High Price Close Price Previous Close
13.46 13.45 13.97 13.94 13.105
more quote information »

Recent News

Date Time Source Heading
25/4/202420:30BWSage Therapeutics Announces First Quarter 2024 Financial..
17/4/202420:30BWSage Therapeutics Announces Topline Results from Phase 2..
11/4/202420:30BWSage Therapeutics to Report First Quarter 2024 Financial..
28/2/202422:30BWSage Therapeutics to Present at Upcoming March Investor..
22/2/202408:35EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
16/2/202409:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202409:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202408:09EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
14/2/202423:49EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/2/202423:20EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
14/2/202422:45EDGAR2Form 8-K - Current report
14/2/202422:30BWSage Therapeutics Announces Fourth Quarter and Full Year..
01/2/202409:25EDGAR2Form SC TO-I/A - Tender offer statement by Issuer: [Amend]
01/2/202408:50EDGAR2Form 8-K - Current report
31/1/202422:30BWSage Therapeutics to Report Fourth Quarter and Full Year..
25/1/202408:10EDGAR2Form 8-K - Current report
24/1/202400:13EDGAR2Form SC TO-I - Tender offer statement by Issuer
08/1/202422:45EDGAR2Form 8-K - Current report
08/1/202422:32BWSage Therapeutics to Provide Business Updates at 42nd Annual..
08/1/202422:30BWSage Therapeutics Announces Changes to Board of Directors
05/1/202408:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202422:30BWSage Therapeutics to Present at the 42nd Annual J.P. Morgan..
20/12/202300:32EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
20/12/202300:30EDGAR2Form DEF 14A - Other definitive proxy statements
14/12/202322:30BWZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for..
09/12/202301:00EDGAR2Form SC TO-C - Written communication relating to an issuer..
09/12/202300:30EDGAR2Form PRE 14A - Other preliminary proxy statements
08/11/202322:30BWSage Therapeutics to Present at Upcoming November Investor..
07/11/202323:39EDGAR2Form 8-K - Current report
07/11/202323:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/11/202323:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202322:46EDGAR2Form 8-K - Current report
07/11/202322:30BWSage Therapeutics Announces Third Quarter 2023 Financial..
24/10/202321:30BWSage Therapeutics to Report Third Quarter 2023 Financial..
18/10/202322:10DJNSage Therapeutics Gets FDA Orphan Designation for SAGE-718..
18/10/202321:30BWSage Therapeutics Announces U.S. Food and Drug..
06/9/202320:30BWSage Therapeutics to Present at Upcoming September Investor..
31/8/202320:45EDGAR2Form 8-K - Current report
31/8/202320:30BWSage Therapeutics Implements Strategic Reorganization to..
11/8/202322:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202321:51IHMARKETNEWSTuesday’s Wall Street Highlights: Novo Nordisk, RingCentral,..
07/8/202322:18DJNSage Therapeutics Shares Slide Premarket After Zurzuvae MDD..
07/8/202321:49EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/8/202321:26IHMARKETNEWSMonday’s Wall Street Highlights: Berkshire Hathaway, Tesla,..
07/8/202321:23DJNSage Therapeutics Mulls Job, Pipeline Cuts After FDA..
07/8/202320:45EDGAR2Form 8-K - Current report
07/8/202320:30BWSage Therapeutics Announces Second Quarter 2023 Financial..
05/8/202312:45BWSage Therapeutics to Host Business Update Webcast and..
05/8/202312:42BWFDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral..
05/6/202320:30BWSage Therapeutics to Present at the Goldman Sachs 44th..

Your Recent History

Delayed Upgrade Clock